Filing Flows › Syndax Pharmaceuticals (SNDX) › Q2 2026 › vs Q2 2025
Syndax Pharmaceuticals (SNDX) Q2 2026 vs Q2 2025 (year over year)
Syndax Pharmaceuticals's revenue rose $34.8M (+92%) from $38.0M in Q2 2025 to $72.8M in Q2 2026. The biggest changes: Product +$26.1M (+91%); Collaboration Revenue +$8.7M (+93%).
Syndax Pharmaceuticals, Q2 2026: revenue $72.8M (+92% year over year), operating margin -54.9%, net loss $49.4M, operating cash flow −$30.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $54.7M | $28.6M | $26.1M | +91% |
| Collaboration Revenue | $18.1M | $9.4M | $8.7M | +93% |
| Revenue | $72.8M | $38.0M | $34.8M | +92% |
| Net loss | $49.4M | $71.8M | −$22.5M | -31% |
| Costs & expenses | $122M | $110M | $12.3M | +11% |
| Operating costs | $113M | $107M | $5.5M | +5% |
| Interest & other, net | $9.4M | $2.5M | $6.9M | +276% |
| Research & development | $68.0M | $62.2M | $5.8M | +9% |
| General & admin | $41.5M | $43.8M | −$2.3M | -5% |
| Other operating costs | $3.2M | $1.3M | $1.9M | +151% |
| Operating cash sources | $49.4M | $71.8M | −$22.5M | -31% |
| Depreciation | $5.0M | $0 | $5.0M | — |
| Share-based compensation | $14.0M | $13.8M | $226K | +2% |
| Working capital & other | $78K | −$29.7M | $29.8M | — |
| Cash used in operations | $30.3M | $87.8M | −$57.5M | -66% |
| Net loss absorbed | $49.4M | $71.8M | −$22.5M | -31% |
Questions
How much did Syndax Pharmaceuticals's revenue grow year over year in Q2 2026?
Syndax Pharmaceuticals's revenue rose $34.8M (+92%) from $38.0M in Q2 2025 to $72.8M in Q2 2026.
What drove Syndax Pharmaceuticals's revenue change in Q2 2026?
Product +$26.1M (+91%); Collaboration Revenue +$8.7M (+93%).